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Abstract
Background: Despite the heavy burden and impact of the polycystic ovary syndrome (PCOS) in reproduction and
public health, estimates regarding its prevalence at community levels are limited. We aimed to ascertain prevalence
of PCOS in a community based sample using the National Institute of Health (NIH), the Rotterdam consensus
(Rott.) and the Androgen Excess Society (AES) criteria.
Methods: Using the stratified, multistage probability cluster sampling method, 1126 women were randomly
selected from among reproductive aged women of different geographic regions of Iran. PCOS were diagnosed
using universal assessment of ultrasonographic parameters, hormonal profiles and clinical histories.
Results: The mean +/- SD of age of study population was 34.4 +/- 7.6 years. Estimated prevalence of idiopathic
hirsutism was 10.9% (95% CI: 8.9-12.9%); 8.3% of women had only oligo/anovulation and 8.0% had only polycystic
ovaries. The prevalence of PCOS was 7.1% (95% CI: 5.4-8.8%) using the NIH definition, 11.7% (95% CI: 9.5-13.7%) by
AES criteria and 14.6% (95% CI: 12.3-16.9%) using the Rott definition.
Conclusions: At community level, widespread screening of Rotterdam criteria will increase the estimated
prevalence of PCOS over twofold. Establishing an explicit and contemporaneous method for definition and
screening of each PCOS criteria has important investigational implications and increase the comparability of
published research.
Background
Polycystic ovary syndrome (PCOS) is the most common
gynecological endocrinopathy [1,2]. Women with PCOS
are at increased risk of reproductive problems including
infertility, endometrial cancer, late menopause [3-6] and
also metabolic aberrations, including insulin resistance,
type 2 diabetes mellitus, dyslipidemia and cardiovascular
diseases [7-10].
Despite the heavy burden and impact of the polycystic
ovary syndrome (PCOS) in reproduction and public
health, estimates regarding its prevalence are limited;
considering the controversy regarding its diagnostic cri-
teria and difficulties in conducting prevalence studies at
community levels, data on its current prevalence are
questionable [11]. The reported prevalence of PCOS
ranges between 2.2% to 26%in various countries,
depending on the recruitment process of the study
population, the criteria used for its definition and the
method used to define each criterion [1,11-21]. Recruit-
ment strategy affects the types of subjects enrolled in a
study; e.g. recruiting the subjects using the promise of a
health evaluation [19]may potentially bias the results
toward disease-carrying individuals. Considering that the
Rott. versus NIH criteria increases the PCOS prevalence
by 1.5-2 times [21,22], its prevalence may be influenced
by using various definitions and the screening method
for identification of androgen excess or ovulatory dys-
function [11,14,23]; unless universal screening for hyper-
androgenemia or subclinical oligo/anovulation is
conducted, identification of these conditions can easily
be overlooked [24,25]. There are significant ethnic and
racial variations in the clinical presentation of PCOS
[26,27]and the Ferriman-Gallwey (F-G) score of
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excess in some ethnic groups [28]. East Asians are typi-
cally less hairy than Euro-Americans, which may be
explained by low levels of 5a-reductase activity in the
skin of those women [29].
To the best of our knowledge there is no population
based study that estimates the prevalence and clinical
characteristics of PCOS in the Eastern Mediterranean
Region. The objective of the present study was to deter-
mine the prevalence of PCOS under the NIH, Rott.
and the AES criteria, in a well-defined, non-selected
population of Iranian reproductive aged women, using
universal assessment of ultrasonographic parameters,
hormonal profiles and clinical histories.
Methods
Study subjects and the sampling method
Sample size was calculated based on these parameters:
P = 0.085 [5], a = 0.95, d = 0.025, cluster design effect =
2 and a non response rate = 0.15. A stratified, multistage
probability cluster sampling method, with a probability
in proportion to size procedure, was used. The frame
for the selection of the sampling units was based on the
Iranian household lists available in the Health Depart-
ment. The information regarding the age, sex, and mari-
tal status of each family member is available in this list
and updated annually. Selecting the cluster was made
systematically and the starting points for the survey in
each cluster were determined centrally.
A total of 1126 women, aged 18-45 years, were
recruited from among reproductive aged women living
in urban areas of four randomly selected provinces of
different geographic regions i.e. Ghazvin (Central),
Kermanshah (East), Golestan (North) and Hormozgan
(South). The age and sex distribution of the population
of these provinces is representative of national general
population based on 2006 national population and hous-
ing census of Iran. Menopausal women, those who had
undergone hysterectomy or bilateral oophorectomy and
pregnant women were excluded (n = 90). To minimize
the effect of treatment bias, all other women, regardless
of hormonal therapy including insulin sensitizers and
oral contraceptive pills were included, but their hormo-
nal and biochemical parameters were not considered for
statistical analysis.
Study protocol
Pairs of trained staff members of local medical universi-
ties/schools (midwives) served as interviewers, and a
trained supervisor monitored the process in each dis-
trict. The interviewers, thoroughly explained the pur-
pose and procedure of the study to subjects and
obtained their consent and a checklist questionnaire,
based on the inclusion and exclusion criteria, was
completed at subjects’ homes (n = 1126). Women who
met the inclusion criteria (n = 1036) were invited to a
referral clinic in each province for a comprehensive
interview and physical exam. Ninety seven eligible
women who signed the inform consent did not came to
the clinics, as a result the response rate of our study
was 91%. For those eligible women who referred to
clinics (n = 939) a standard questionnaire including
demographic and reproductive variables, with emphasis
on regularity of menstrual cycle, gynecological history,
hyperandrogenic symptoms, family history of irregular
menstrual cycle and hirsutism was completed, during
face-to-face interviews by trained midwives under super-
vision of a gynecologist. The hirsutism scores were
assessed using the modified Ferriman-Gallwey (mFG)
scoring method [30]. Acne was scored based on its
number, type, and distribution [31].The menstrual cycle
of subjects on hormonal medication was evaluated by
questioning about menstrual regularity before starting
medication. To maximize the accuracy of hirsutism
scoring, subjects with an initial mF-G score more than 3
per the study midwives and/or those women with men-
strual dysfunction were reexamined by a single gynecol-
ogist in each province.
All participants underwent clinical examinations,
where body weight, height, waist (WC), hip circumfer-
ences (HC) and blood pressure were measured. Body
mass index was calculated as weight in kilograms
divided by the height in meters squared (kg/m
2).
An overnight fasting venous blood sample was
obtained from each subject on the second or third day
of their spontaneous or progesterone induced menstrual
cycles (n = 929). All sera were stored at -80°C until the
time of measurements.
All of the study subjects were invited for transvaginal
(n = 760) or transabdominal (n = 169) ultrasound scans
of the ovaries, which were performed using the
3.5-MHz transabdominal and 5-MHz transvaginal trans-
ducer by an experienced sonographer in each province
and all scans were assessed by a single sonographer.
Ultrasound was performed as the same day as the blood
samples were collected.
Measurements
Dehydroepiandrosterone sulfate (DHEAS), 17-hydroxy-
progesterone (17OH-P), Total testosterone (TT) and
Androstendion(A4) were measured by enzyme immunoas-
say (EIA), (Diagnostic biochem canada Co. Ontario,
Canada). Sex Hormone Binding Globulin (SHBG) was
measured by immunoenzymometric assay (IEMA), (Mer-
codia, Uppsala, Sweden). All ELISA tests were performed
using Sunrise ELISA reader (Tecan Co. Salzburg, Austria).
Luteinizing hormone (LH), Follicle stimulating hormone
(FSH), Prolactin (PRL), and Thyroid stimulating hormone
Tehrani et al. Reproductive Biology and Endocrinology 2011, 9:39
http://www.rbej.com/content/9/1/39
Page 2 of 7(TSH) was measured by immunoradimetric assay (IRMA),
(Izotop, Budapest, Hungary) using gamma counter Wallac
Wizard, Turku, Finland).
It has been shown that in women the free androgen
index (FAI) has a good correlation with free testosterone
measured by physical separation method [32]; therefore
FAI was calculated using the formula [TT (nmol/L) ×
100/SHBG (nmol/L)]. The intra- and inter-assay coeffi-
cients of variation for TT were 5.6% and 6.6%; for
DHEAS: 2.0% and 5.1%; for 17 OH-P: 4.8% and 6.8%;
for SHBG: 1.2% and 5.7%; for A4: 2.2% and 3.5%; for
LH- 3% and 5.8%; for FSH: 3.5% and 4%; for TSH: 1.7%
3.4%, and for PRL, they were 2.1% and 4.1%.
Definitions
We defined PCOS in our study using the NIH [33],
Rott. [34] and AES criteria [35]. Using the NIH criteria,
PCOS was defined as the combination of chronic anovu-
lation (ANOVU) and clinical hyperandrogenism and/or
hyperandrogenemia (HA). By Rott. criteria, PCOS was
defined by the presence of two or more of the following:
1) Oligo/anovulation (ANOVU), 2) Hyperandrogenemia
and/or hyperandrogenism (HA), and 3) Polycystic ovar-
ies (PCO). Using the AES definition, PCOS was diag-
nosed by the presence of clinical and/or biochemical
hyperandrogenism (HA) with ovarian dysfunction
defined as oligo/anovulation (ANOVU) and/or polycys-
tic ovaries (PCO). Hyperprolactinemia, thyroid dysfunc-
tion, and nonclassic 21-hydroxylase deficiency were
excluded in all of the women who achieved the other
criteria for the diagnosis of PCOS.
ANOVU was considered as vaginal bleeding episodes at
no less than 35-day intervals [36,37]. HA was determined
as clinical hyperandrogenism (CH) and/or biochemical
hyperandrogenemia (BH). CH was defined by the pre-
sence of hirsutism (mF-G ≥8) [30], acne, or the presence
of androgenic alopecia. BH was detected by FAI and/or
DHEAS and/or A4 level, above the upper 95th percentile
for the 362 women studied, who were not on any hormo-
nal medication and had no clinical evidence of hyperan-
drogenism, ANOVU and PCO. Specifically, the upper
normal limits were total T = 0.88 ng/ml, A4 = 2.3 ng/ml,
DHEAS = 246 μg/dL and FAI = 5.47
PCO was diagnosed by the presence of 12 or more
follicles in each ovary, measuring 2-9 mm in diameter
and/or increased ovarian volume (10 cm3) [38,39].
Idiopathic hirsutism(IH) was defined as hirsutism
without ANOVU and/or PCO [24]. BH plus hirsutism
was defined as hirsutism with BH without PCOS, using
the Rott.definition [40].
Primary infertility was defined as the having the his-
tory of trying to conceive for at least one year without
success despite of regular sexual intercourse, no use of
contraception and no previous pregnancy.
Statistical analysis
Continuous variables were checked for normality using
t h eo n e - s a m p l eK o l m o g o r o v - S m i r n o f ft e s t ;t h e ya r e
expressed as mean ± standard deviation and/or median
and interquartile ranges, as appropriate. The categorical
variables are expressed as percentages. Distributions
between groups are compared using the Kruskal-Wallis
test, followed with Mann-Whitney test with Bonferroni
correction for pair wise comparison. The categorical
variables are compared using the Pearson’s c
2 test. Data
analysis was performed using the SPSS 15.0 PC package
(SPSS Inc., Chicago, IL).
The ethical review board of the Research Institute for
Endocrine Sciences has approved the study proposal and
informed consent was obtained from all subjects.
Details of Ethics Approval
The ethical review board of the Research Institute for
Endocrine Sciences has approved the study proposal
(approved number: 47854 Date: 15/12/2007) and
informed consent was obtained from all subjects.
Results
A study checklist was completed for 1126 women, aged
18-45 years. Figure 1 outlines the data collection proce-
dure. Of 1036 women who met our inclusion criteria,
929 ones completed the study procedure. The mean age
of study population was 34.4 years. There was 65
women who used oral contraceptive pill, 61 did so solely
for the purpose of contraception.
Of a total of 929 women, 423(45.5%) subjects were
eumenorrheic and did not have HA and or PCO (nor-
mal), 205 (22.1%) women had only HA and overall, 3.5%
of all women had acne. Seventy-seven (8.3%) women
h a do n l yA N O V Ua n d7 4( 8 . 0 % )w o m e nh a do n l yP C O
in ultrasonography; the estimated prevalence of IH was
10.9% (95% CI: 8.9-12.9%) (Figure 1).Out of 929 study
participants, 136 women met Rott criteria therefore the
prevalence of PCOS using Rott. criteria was 14.6% (95%
CI: 12.3- 16.9%). There was 109 women with PCOS
based on AES criteria, as a result the prevalence of
PCOS was 11.7% (95% CI: 9.5- 13.7%) using AES defini-
tion. Out of 929 study participants, 66 women met NIH
criteria therefore the prevalence of PCOS using NIH cri-
teria was 7.1% (95% CI: 5.4 -8.8%). There were not any
suspicious cases of congenital adrenal hyperplasia,
androgen-secreting tumors and Cushing’ss y n d r o m e
based on physical exam and hormonal assessment.
Basic, reproductive and metabolic characteristics of
those who had various phenotypes of PCOS using Rott.
criteria in comparison to normal women are shown in
Table 1. Compared to their normal counterparts, the
prevalence of primary infertility was about two to three
times higher among women with PCOS. The familial
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lent in group 1 (ANOVU+ HA +/-PCO) phenotype in
comparison to normal subjects (Table 1).
From among 314 (33.8%) women who had HA in our
study, 109 had PCOS using Rott. definition (Figure 1).Of
these PCOS women, 54 ones had only CH, 18 women
had both CH and BH and the reminding 37 had pure
BH (14 pure FAI excess, 6 pure A4 excess, 2 pure
DHEAS excess and 15 mixed androgen excess). Of these
37, 8 women would possibly have remained undiag-
nosed, had we not assessed the serum concentrations of
androgens in women without oligo/anovulation.
Discussion
The prevalence of PCOS was 7.1% (95% CI: 5.4 -8.8%)
using the NIH definition, 11.7% (95% CI: 9.5- 13.7%) by
AES criteria and 14.6% (95% CI: 12.3- 16.9%) using the
Rott. criteria in our sample of an Iranian population. To
the best of our knowledge there is no study in the East-
ern Mediterranean Region that estimates the prevalence
and clinical characteristics of PCOS among an unse-
lected population.
The reported prevalence of PCOS in various geo-
graphic regions ranges between 2.2% to 26% [1,11-21].
In Southern China the prevalence was 2.4% among 915
women recruited through the offer of a free medical
examination using Rott criteria [14]; it was 6.5% among
154 white blood donor women in Spain using NIH cri-
t e r i a[ 1 8 ] ,I nt h es t u d yb yA z z i ze ta l .o fw o m e nu n d e r -
going a preemployment physical examinations in the
United States, the cumulative prevalence of PCOS was
6.6% using the NIH definition [1]; the prevalence of
PCOS using Rott. definition was reported to be 17.8%
among 978 women, who were recruited in a retrospec-
tive birth cohort study in South Australia [11]. Among
157 women with type 2 diabetes in Esfahan-Iran, the
prevalence of PCOS was 8.2% [41].
The PCOS prevalence depends on the recruitment
process of the study population and criteria used for its
definition; in the present study considering the Rott.
Check list was filled up for 1126 women age 18-45
1036 eligible women
939women completed the physical exam and 
questionnaire
929 women completed hormonal assessment and 
ultrasonography
Excluded n=90
Natural/surgical menopause n=37 
pregnancy n=43, Others n=10
Refused to participate  n=97
Not completed hormonal assessment 
and ultrasonography n=10
Normal
n=423
PCO
n= 156
HA
n=314
AVOVU
n=170
Hypothyroid n=10, 
hyperprolactinemia 
n=4
ANOVU
only
n=77
PCO
only
n=74
HA only 
n=205
AVOVU
+ PCO 
N=27
HA+
PCO
N=43
Full Rott. 
criteria
N=12
IH
n=101 (BH  + CH) n=104
HA + 
ANOVU
N=54
Figure 1 An overview of study cohort. ANOVU, oligo/anovulation; HA, biochemical hyperandrogenemia and/or clinical hyperandrogenism;
PCO, polycystic ovaries; IH, idiopathic hirsutism; CH, clinical hyperandrogenism; BH, biochemical hyperandrogenemia; Full Rott. criteria Women
with all of these three criteria: ANOVU, HA, and PCO.
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as reported before [21,22]
, [42-44]. Furthermore the
definition of each criteria and its screening method has
a considerable impact on PCOS prevalence at the com-
munity level [1,11,16]. There was not any agreement
regarding the cut off value for F-G score as a criterion
for clinical hyperandrogenism or the menstrual cycles’
intervals as a criterion for ANOVU, furthermore there
are no agreed definition of hyperandrogenism. In our
study, clinical hyperandrogenism was determined as mF-
G ≥8 and ANOVU was defined as vaginal bleeding epi-
sodes at no less than 35-day intervals; some of the other
investigators used different cut of points for these defi-
nitions [11,14]; e.g. the clinical hyperandrogenism was
defined as mF-G ≥6 by Knochenhauer et al. [16] and as
mF-G ≥7 DeUgarte et al. [28]. We did not measured the
mid luteal phase serum progesterone and it has been
shown that 14-40% of eumenorrheic women with andro-
gen excess and 3.7% of eumenorrheic, non hirsute
women have oligoovulatory cycles diagnosed by serum
concentration of progesterone [24,25,45]. Therefore, the
number of ANOVU women in our study might have
been increased from 170 to 222 [(205 × 25%) + (423 ×
3.7%)] had we assessed mid luteal phase serum proges-
terone. To verify hyperandrogenemia, we measured
serum concentration of all types of androgens among all
our participants, regardless of regularity of their men-
strual cycles; if serum concentration of androgen was
assessed only among women with ANOVU, or if we did
not measure all types of androgens, 8 out of 37 women
with only BH would have remain undiagnosed. It seems
that the widespread screening of PCOS criteria has a
considerable impact on its estimated prevalence at the
community level. Recognition of these mild phenotypes
of PCOS is a challenging issue and its effectiveness
must be evaluated from several perspectives, including
the researcher’s, clinician’s, and the patient’s. Azziz et al
suggested widespread screening for earlier diagnosis and
possibly prevention of serious consequences [46]. How-
ever this needs to be confirmed through further well
design studies.
The reported prevalence of idiopathic hirsutism varies
from 5-29% [19,47]. In the present study, 22.4% of
women had only hirsutism, half of them having pre-
sented with IH; these women cannot be entirely
excluded from the diagnosis of PCOS, because they may
have been oligoovulatory, despite of their reported regu-
lar episodes of vaginal bleeding [48].
The main strength of the present study is its metho-
dology, as it is a community based prevalence study car-
ried out on an ethnically homogenous population and
had an appropriate response rate of 91%. The majority
of previous studies on PCOS have relied upon a conve-
nience sample of applicants for university employment
[1,16], blood donors [18] or individuals recruited
through publicity campaigns [19]. Similar to those
reported by Janghorbani et al following a large national
survey [49], the educational status and the prevalence of
Table1 The characteristics of various phenotypes of PCOS using Rotterdam criteria
Phenotype characteristic Group 1 (n = 66) ANOVU+ HA
± PCO
Group2 (n = 43) HA +
PCO
Group3 (n = 27) ANOVU
+ PCO
Normal (n =
423)
Age (years) 31.0 (25.8-37.3)* 30.0 (25.0-40.0)* 35.0 (28.0-39.0) 36.0 (30.0-41.0)
BMI (kg/m2) 27.0 (25.8-37.3) 25.0 (21.6-29.2) 25.6 (23.0-31.2) 26.4 (23.1-29.4)
WHR 0.81 (0.76-0.85) 0.78 (0.75-0.85) 0.83 (0.78-0.86) 0.81 (0.76-0.85)
Systolic Blood Pressure (mm/Hg) 110.0 (100.0-120.0) 100.0 (105.0-110.0) 110.0 (100.0-110.0) 110.0 (100.0-
120.0)
Diastolic Blood Pressure (mm/Hg) 70.0 (60.0-80.0) 70.0 (60.0-70.0) 70.0 (60.0-70.0) 70.0 (60.0-80.0)
% Women with history of Primarily
infertility
27.3* 21.6* 31.0* 10.6
% women with family history of HA 42.4* 20.9 11.1 14.0
% women with family history of
ANOVU
36.4*†‡ 14.0 22.2 19.0
LH/FSH Ratio 0.77 (0.46-1.04) 0.64 (0.45-1.0) 0.69 (0.5-1.1) 0.6 (0.43-0.86)
Total T (ng/ml) 0.75 (0.57-0.88) *‡ 0.81 (0.52-0.93) *†† 0.41 (0.29-0.53) 0.51 (0.32-0.68)
FAI 4.7 (3.1-6.9) *‡ 4.9 (3.6-7.1) *†† 2.2 (1.3-2.8) 2.6 (1.5-3.7)
A4 (ng/ml) 5.8 (5.1-6.9) *‡ 2.1 (1.8-2.5) *†† 1.1 (0.9-2.0) 1.1 (0.9-1.7)
DHEAS (μg/Dl) 196.1 (149.5-238.1) *‡ 200.5 (138.9-248.0) *†† 141.5 (45.7-186.7) 138.0 (58.3-
192.8)
SHBG (nmol/L) 54.8 (42.7-70.7) * 54.4 (45.0- 67.1) * 62.6 (49.1-88.1) 67.2 (53.4-92.4)
Values are given as median (Inter quartile range), +The hormonal and biochemical assessments of those women who use insulin sensitizers and/or oral
contraceptive pills were not included for statistical analysis. * = versus normal group, p < 0.008, † = Group1 versus Group2, P < 0.008; ‡ = Group 1 versus Group
3; ††= Group2 versus Group3, p < 0.008; WHR, waist to hip ratio; Normal group, eumenorrheic and without HA and PCO; ANOVU, oligo/anovulation; HA,
hyperandrogenemia and/or hyperandrogenism; PCO,polycystic ovaries; DHEAS, Dehydroepiandrosterone sulfate; Total T, Total testosterone; A4, Androstendion;
SHBG, Sex Hormone Binding Globulin; FAI, Free androgen index.
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our population as being representative of Iranian repro-
ductive aged women. This study also has the advantage
of assessment of androgens in all participants, regardless
of their menstrual pattern; hence it was unlikely that
any hyperandrogenemic subjects were overlooked. The
amount of intra-assay variability in our data is also likely
to be minimal because all the laboratory measurements
were done at the same laboratory by the same person.
Our study does have some limitations; we did not use
the menstrual diary to identify menstrual intervals and
we did not measure progesterone to identify eumenor-
rheic women, who had subclinical menstrual dysfunc-
tion; our results may therefore be underestimates; for
some cases, socio-cultural constraints precluded a vagi-
nal approach for ultrasonography and as a result a spe-
cific and sensitive tool was not used for determining the
polycystic ovaries. We did not have any information
about those few women who refuse to participate in our
study, which may also have affected our estimates.
Conclusions
This study shows that widespread screening of Rotter-
dam criteria, at the community level, will increase the
estimated prevalence of PCOS over twofold. Establishing
a clear and contemporaneous method for screening and
recognition of PCOS criteria is essential for improving
the comparability and potentially the value of published
research.
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